Population-based Screening for BRAF V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis.

Jenny E Chu Benny JohnsonLaveniya KugathasanVan Karlyle MorrisKanwal RaghavLucas A SwansonHoward J LimDaniel J RenoufSharlene GillRobert WolberAly KarsanScott KopetzDavid F SchaefferJonathan M Loree

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Patients with BRAF V600E-mutated mCRC have a worse prognosis than previously suggested, potentially arising from referral bias for testing. High attrition between lines of therapy suggests efficacious therapies need to be prioritized early for patients to benefit.

Keyphrases

metastatic colorectal cancer
poor prognosis
long non coding rna
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
primary care
risk factors
prognostic factors
stem cells